投资者关系活动记录表 证券代码：300630 证券简称：普利制药 海南普利制药股份有限公司投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |----------------|-----------------------------------|-----------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | 胡博新（国海证券股份有限公司 ）张羽 (九泰基金管理有 | | 人员姓名 | 限公司 ) | | | | | 周超泽（国海证券股份有限公司 ）何豪杰 (北京市星石投 | | | 资管理有限公司 ) | | | | 向秋静 (兴业证券股份有限公司 | ) 沈瑞 (财通证券股份有限 | | | 公司 ) | | | | 汤潇 ( 九泰基金管理有限 ...

投资者关系活动记录表 证券代码：300630 证券简称：普利制药 海南普利制药股份有限公司投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | √ | 其他（深交所在公司举办"践行中国梦·走进上市公司" 投资 | | | 者开放日） | | | 参与单位名称及 | 1 | 、国元证券、华福证券、湘财证券、国泰君安证券、东方证 | | 人员姓名 | | 券、中信建投证券、上海证券等报名的投资者 | | | 2 视台等记者 | 、第一财经、全景网、中国证券报、证券日报、广东广播电 | | | 3 、深圳证券交易所领导 | | | | | | | 时间 | 2018 年 1 ...

投资者关系活动记录表 证券代码：300630 证券简称：普利制药 海南普利制药股份有限公司投资者关系活动记录表 编号：2018-002 | --- | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------|-------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | | 类别 | □ | 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | □ | 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | 南方基金、上实投资、民森投资、富国基金、上海国际信托、 | | | 人员姓名 | 信达证券、工银瑞信等投资者； | | | | | | 海通证券、广发证券、中信银行、信达证券等金融机构； | | | | | 全景网、新财富、证券时报等媒体； | | | 时间 | 2018 年 5 月 15 | ...

Revenue and Profit - Revenue for Q3 2022 reached ¥575,087,948.20, an increase of 11.97% year-over-year, while year-to-date revenue totaled ¥1,370,691,220.82, up 20.59% compared to the same period last year[7]. - Net profit attributable to shareholders for Q3 2022 was ¥167,852,734.59, reflecting a 1.70% increase year-over-year, with a year-to-date net profit of ¥455,464,130.48, up 16.73%[7]. - Basic earnings per share for Q3 2022 were ¥0.38, up 2.70% year-over-year, while diluted earnings per share also stood at ¥0.38[7]. - Total operating revenue for the current period reached ¥1,370,691,220.82, an increase of 20.6% compared to ¥1,136,643,420.66 in the previous period[28]. - Net profit for the current period was ¥455,464,130.48, representing a 16.7% increase from ¥390,176,301.10 in the previous period[30]. - Basic and diluted earnings per share were both ¥1.04, compared to ¥0.89 in the previous period[33]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline, with a year-to-date net cash flow of ¥82,185,693.73, down 47.55% compared to the previous year[7]. - Cash flow from operating activities totaled ¥1,274,245,066.13, a decrease from ¥1,417,676,860.54 in the previous period[34]. - The net cash flow from operating activities was 82,185,693.73, a decrease of 47.5% compared to 156,679,118.33 from the previous period[37]. - The total cash and cash equivalents at the end of the period were 144,734,657.17, down from 623,880,152.83, reflecting a significant decrease[37]. - The company's cash and cash equivalents decreased to CNY 184.01 million from CNY 442.26 million, representing a decline of approximately 58.4%[21]. Assets and Liabilities - Total assets increased to ¥5,605,973,210.82, representing a growth of 20.24% from the end of the previous year[7]. - The total assets amounted to ¥5,605,973,210.82, compared to ¥4,662,239,616.98 in the previous period[27]. - The company's equity attributable to shareholders rose to ¥2,867,008,388.53, marking a 12.80% increase from the end of the previous year[7]. - The total liabilities reached ¥2,738,964,822.29, an increase from ¥2,120,484,168.47 in the previous period[27]. - The company’s total liabilities increased to CNY 1.16 billion, compared to CNY 1.04 billion, representing a rise of about 11.3%[24]. Accounts Receivable and Inventory - Accounts receivable increased by 42.20% to ¥1,245,343,655.06, attributed to the expansion of business scale[12]. - Accounts receivable increased significantly to CNY 1.25 billion, up from CNY 875.76 million, indicating a growth of around 42.2%[21]. - Inventory levels rose by 46.57% to ¥384,257,012.35, indicating an increase in raw material stockpiling[12]. - Inventory rose to CNY 384.26 million, compared to CNY 262.17 million, marking an increase of approximately 46.5%[24]. Borrowings and Financing - Long-term borrowings surged by 248.78% to ¥639,557,744.96, reflecting increased financing activities[12]. - The company's short-term borrowings increased to CNY 538.29 million from CNY 347.11 million, reflecting a rise of about 55.0%[24]. - The net cash flow from financing activities was 477,193,943.52, a decrease of 47.4% from 905,996,049.53 in the previous period[37]. Government Subsidies and Expenses - The company reported government subsidies of ¥21,147,279.58 year-to-date, an increase of 185.19% compared to the previous year[12]. - Research and development expenses amounted to ¥258,238,348.53, up from ¥204,105,266.69 in the previous period[30]. - Financial expenses increased significantly to ¥63,728,301.67, compared to ¥27,098,855.39 in the previous period[30]. - The cash paid for various taxes was 198,727,567.27, up from 116,900,148.43, representing an increase of 69.9%[37]. - The cash paid to employees and for employee benefits was 121,984,431.11, compared to 77,817,173.17, marking an increase of 56.6%[37].

Financial Performance - The company's operating revenue for the reporting period reached ¥795,603,272.62, representing a year-on-year increase of 27.69% compared to ¥623,056,090.07[26]. - The net profit attributable to shareholders was ¥287,611,395.89, up 27.75% from ¥225,135,214.40 in the same period last year[26]. - The basic earnings per share increased to ¥0.66, reflecting a growth of 26.92% compared to ¥0.52 from the previous year[26]. - Total assets at the end of the reporting period amounted to ¥5,406,277,436.29, marking a 15.96% increase from ¥4,662,239,616.98 at the end of the previous year[26]. - The weighted average return on equity for the reporting period was 10.71%, slightly up from 10.53% in the previous year[26]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization measures[68]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the first half of 2022, representing a 20% year-over-year growth[68]. - The company has provided guidance for the second half of 2022, projecting a revenue growth of 10% to 12% compared to the first half[80]. Research and Development - The company is involved in the development of new products and technologies to improve its competitive edge[1]. - The company has a total of over 140 ongoing research projects, focusing on first generics, modified new drugs, and new chemical entities[42]. - The R&D team consists of 482 personnel, accounting for over one-third of the total workforce of 1,386 employees[53]. - The company is focusing on high-difficulty generic drugs and innovative drugs, with significant R&D investments aimed at developing high-value products[46]. - The company has established a standardized management system for the entire R&D process, ensuring smooth progress towards R&D goals[88]. - The company has a comprehensive R&D process that includes project responsibility systems and competitive evaluation methods, ensuring high standards in product development and registration[117]. - The company is focusing on research and development of new drugs, with a significant number of projects aimed at addressing unmet medical needs in various markets[100]. Market Expansion - The company is focused on expanding its market presence and enhancing its product offerings[1]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[70]. - The company is actively pursuing market expansion strategies in both domestic and international markets to enhance its competitive edge[104]. - The company is expanding its market presence in Europe, with plans to enter three new countries by Q4 2022, aiming for a 5% market share in these regions[82]. - The company has established close communication channels with drug regulatory agencies in nearly 20 countries, with over 10 products approved by the FDA within 10 months of submission[60]. Quality Management - The company has established a comprehensive quality management system and has passed various international quality audits, including those from the FDA and EMA[38]. - The company emphasizes quality control throughout the drug development and production process, which is critical for maintaining its market position[110]. - Each batch of products undergoes strict quality inspection before being released for sale, ensuring compliance with quality standards[96]. - The company has obtained several GMP/cGMP certifications for its raw materials and finished products, ensuring high-quality standards in production[110]. Corporate Governance - The company has a commitment to ensuring the accuracy and completeness of its financial reports, with all board members present for the review[6]. - The company has maintained its information disclosure practices without changes during the reporting period[22]. - The company emphasizes the importance of risk management and has outlined potential risks and corresponding countermeasures in its report[6]. - The company is committed to complying with the disclosure requirements set forth by the Shenzhen Stock Exchange regarding pharmaceutical and biological products[97]. Social Responsibility - The company actively engages in social responsibility initiatives, promoting health and wellness among employees through various cultural activities[188]. - The company donated a total of 133,000 pieces of essential medical supplies during the COVID-19 pandemic, including protective clothing and N95 masks, to support epidemic prevention efforts in Hainan Province[195]. - The company was awarded the "Special Contribution Award" by the China Red Cross for its efforts in combating the COVID-19 pandemic[195]. - The company emphasizes employee rights protection and has implemented a competitive salary structure and stock incentive plans to enhance employee retention and motivation[189]. Environmental Responsibility - The company has established a wastewater treatment system to ensure that all wastewater meets discharge standards before being released[182]. - The company strictly adheres to environmental protection standards and regulations, including the Environmental Protection Law of the People's Republic of China and the Pharmaceutical Industry Water Pollution Discharge Standards[187]. - The company has implemented measures to reduce carbon emissions, including the use of low-noise energy-saving equipment and noise control measures, ensuring compliance with noise emission standards[187]. - The company has implemented a waste management system for hazardous and non-hazardous waste, ensuring proper disposal through qualified third-party services[186]. Investment and Financing - The total investment during the reporting period amounted to RMB 655,505,437.10, representing a 36.36% increase compared to RMB 480,720,106.21 in the same period last year[136]. - The company has invested RMB 43,958,834.36 in the construction of a production line capable of producing 1.5 billion dosage forms, with a cumulative actual investment of RMB 475,193,000.00[137]. - The company has a maximum debt limit of RMB 46,020,000.00 secured by a mortgage on fixed assets, with a loan balance of RMB 45,000,000.00 as of June 30, 2022[133]. - The cumulative realized income from investments as of the reporting period is RMB 634,274,166.93[140].

Financial Performance - The company's operating revenue for 2021 was ¥1,508,829,421.63, representing a 26.94% increase compared to ¥1,188,603,424.51 in 2020[28]. - The net profit attributable to shareholders for 2021 was ¥416,603,057.59, a 2.25% increase from ¥407,450,895.97 in 2020[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥405,675,111.37, up 6.69% from ¥380,235,764.93 in 2020[28]. - The net cash flow from operating activities decreased by 52.71% to ¥157,031,382.42 from ¥332,075,817.29 in 2020[28]. - The total assets at the end of 2021 were ¥4,662,239,616.98, a 52.56% increase from ¥3,055,999,316.62 at the end of 2020[28]. - The net assets attributable to shareholders at the end of 2021 were ¥2,541,755,448.51, a 24.65% increase from ¥2,039,151,308.69 at the end of 2020[28]. - The basic and diluted earnings per share for 2021 were both ¥0.95, a 2.15% increase from ¥0.93 in 2020[28]. - The weighted average return on equity for 2021 was 17.88%, down from 24.02% in 2020, a decrease of 6.14%[28]. - The company reported a total of ¥13,390,856.83 in government subsidies for 2021, down from ¥33,047,459.38 in 2020[35]. Research and Development - The company reported a significant focus on R&D for new products and technologies, aiming to enhance its market position[21]. - The company has over 130 ongoing research projects, including 57 invention patents and 146 product approval numbers, with a focus on generic drugs and improved new drugs[74]. - The R&D team consists of over 450 personnel, accounting for more than one-third of the total workforce, emphasizing the importance of research and development[84]. - The company has established a complete R&D process and system, from project selection to clinical research and registration management[74]. - The company is currently developing several new drugs, including a modified injection for convenience and safety, and a new anti-COVID-19 treatment[139]. - The company has established multiple technical platforms in its raw materials research institute, focusing on specialty raw materials and targeted delivery excipients[91]. - The company has developed a pipeline of nucleic acid drugs leveraging mRNA technology, with preclinical research and clinical application registration ongoing[88]. - The company has initiated a national "14th Five-Year" major project on antiviral polymer nanomedicines, collaborating with several research institutions[88]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to strengthen its portfolio[21]. - The company is focused on expanding its product portfolio with unique formulations, enhancing its market position[61]. - The company is committed to high standards in research and development, ensuring successful product registration and development[74]. - The company is actively pursuing new strategies for market expansion and product development to drive future growth[61]. - The company aims to leverage its high-end production capacity and internationalization strategy to expand its CDMO business[78]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of the year, aiming for a 10% market share in these regions[103]. - The company has signed exclusive sales contracts with distributors in over 20 countries, including the United States, Germany, and the United Kingdom, expanding its international market presence[70]. - The company has received approval for 11 products in the US, with limited global coverage, indicating significant expansion potential in international markets[196]. Product Development and Innovation - The company has entered the registration process for multiple drugs, with 7 projects currently under review in various countries, including Israel, the UK, Thailand, Singapore, and Germany[49]. - The company has successfully registered several new products, including injection formulations and oral tablets, which are expected to enhance market presence and brand influence[56]. - The company is focusing on the development of generics for chronic diseases, which aligns with global healthcare trends and increasing demand for affordable medications[52]. - The company has a robust pipeline with multiple submissions for antifungal and antiviral drugs, reflecting a commitment to expanding its therapeutic offerings[54]. - The company has developed a dual-modal contrast agent for tumor surgery navigation, with clinical approval expected by the end of 2022 in both China and the US[88]. - The company has received FDA approval for its injectable products, including azithromycin and ganciclovir, indicating its capability to meet international quality standards[64]. - The company is actively pursuing consistency evaluations for its anti-infective drugs in China, which may lead to improved market access and competitive positioning[54]. Financial Management and Cost Control - The company has implemented cost-cutting measures that are projected to save approximately 100 million yuan annually, improving overall profitability[99]. - The introduction of a new technology platform is anticipated to streamline operations and reduce production costs by 15% over the next two years[102]. - The company has set a performance guidance of achieving a net profit margin of 18% for the upcoming fiscal year, up from 15%[101]. - The procurement center is responsible for all procurement activities, utilizing various strategies such as bidding and price negotiation to control costs and improve quality[111]. - The company employs a "sales-driven production" model, implementing full-process supply chain management to meet market demands[114]. Sustainability and Compliance - The company is committed to green and low-carbon development in its production processes, aligning with national policies for sustainable growth[47]. - The company emphasizes supplier management, ensuring the selection of reliable suppliers through audits and performance evaluations[113]. - A complete GMP management system has been established to ensure compliance with high standards across all production stages[114]. - The company has obtained FDA and EMA certifications for its raw materials and solid dosage production lines, ensuring compliance with international quality standards[77]. Sales and Revenue Growth - The company reported a significant increase in revenue, reaching a total of 1.5 billion yuan, representing a 20% year-over-year growth[99]. - User data showed an increase in active users, with a total of 3 million new users added in the last quarter, marking a 15% increase compared to the previous quarter[100]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% driven by new product launches and market expansion strategies[102]. - The company aims to achieve a rapid increase in its biotechnology research team from 16 to 50-100 members in 2022, with over 80% of the team holding graduate degrees[88].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 367,925,505.63, representing a 34.58% increase compared to CNY 273,392,371.83 in the same period last year[4] - The net profit attributable to shareholders for Q1 2022 was CNY 161,777,968.14, up 33.44% from CNY 121,239,486.28 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 148,627,173.03, reflecting a 25.53% increase from CNY 118,400,289.91 in the previous year[4] - The basic earnings per share for Q1 2022 was CNY 0.37, which is a 54.17% increase from CNY 0.24 in the previous year[4] - Total operating revenue for the current period reached ¥367,925,505.63, a significant increase of 34.7% compared to ¥273,392,371.83 in the previous period[28] - Operating profit for the current period was ¥167,770,281.15, up 35.8% from ¥123,477,888.03 in the previous period[31] - Net profit attributable to the parent company was ¥161,777,968.14, representing a 33.5% increase from ¥121,239,486.28 in the previous period[34] - Basic and diluted earnings per share increased to ¥0.37 from ¥0.24, reflecting a growth of 54.2%[34] Cash Flow - The net cash flow from operating activities for Q1 2022 was CNY 22,275,788.10, a significant increase of 97.14% compared to CNY 11,299,484.87 in the same period last year[4] - The net cash flow from operating activities was $22,275,788.10, an increase from $11,299,484.87 in the previous period, reflecting a growth of approximately 97.5%[38] - Total cash outflow from operating activities amounted to $335,379,669.36, compared to $259,947,570.35 previously, indicating a rise of about 29%[38] - The net cash flow from investing activities was -$215,463,507.52, an improvement from -$269,422,298.57, showing a reduction in losses by approximately 20%[38] - Cash inflow from financing activities totaled $448,281,111.11, down from $890,330,850.00, representing a decrease of about 49.6%[38] - The net cash flow from financing activities was $224,921,521.49, compared to $759,214,164.72 previously, indicating a decline of approximately 70.4%[38] - The ending balance of cash and cash equivalents was $470,600,079.22, a decrease from $856,254,087.18, reflecting a drop of about 45%[38] - The company reported a cash increase of $31,733,802.07 during the period, compared to an increase of $500,767,809.78 in the previous period[38] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to CNY 4,939,389,761.87, marking a 5.94% increase from CNY 4,662,239,616.98 at the end of the previous year[4] - The total liabilities of the company as of March 31, 2022, were CNY 2,229,657,524.37, up from CNY 2,120,484,168.47, marking an increase of about 5.1%[24] - The company's equity attributable to shareholders at the end of Q1 2022 was CNY 2,709,732,237.50, up 6.61% from CNY 2,541,755,448.51 at the end of the previous year[4] - The company's equity attributable to shareholders rose to CNY 2,709,732,237.50 from CNY 2,541,755,448.51, reflecting an increase of approximately 6.6%[27] - The non-current assets totaled CNY 2,978,498,774.80, up from CNY 2,637,208,856.20, indicating a growth of about 12.9%[21] - Short-term borrowings increased by 34.27% to CNY 466,069,697.24 from CNY 347,114,881.92 in the previous year[8] - Short-term borrowings increased to CNY 466,069,697.24 from CNY 347,114,881.92, representing a rise of approximately 34.3%[21] - The company's contract liabilities increased to CNY 46,588,790.55 from CNY 40,639,330.34, showing a growth of about 14.3%[24] - The total current liabilities were CNY 1,039,435,709.09, slightly down from CNY 1,039,683,193.63, indicating a marginal decrease of about 0.02%[24] Expenses - Research and development expenses increased to ¥56,659,055.19, a rise of 12.9% compared to ¥50,208,146.21 in the previous period[31] - Sales expenses rose to ¥47,706,957.68, an increase of 22.6% from ¥38,904,005.07 in the previous period[31] - Total operating costs for the current period were ¥212,061,775.12, up 38.3% from ¥153,207,132.77 in the previous period[28] - Income tax expenses increased to ¥6,010,278.61 from ¥2,253,300.85, reflecting a rise of 166.5%[31] Other Income and Subsidies - Government subsidies recognized in Q1 2022 amounted to CNY 13,015,588.30, contributing to the increase in other income by 295.29% compared to CNY 3,292,648.97 in the previous year[8] - The company reported other income of ¥13,015,588.30, significantly higher than ¥3,292,648.97 in the previous period[31] Financial Reporting - The report for the first quarter was not audited, which may impact the reliability of the financial data presented[39]

Financial Performance - The company's revenue for Q3 2021 reached ¥513,587,330.59, representing a 35.03% increase compared to the same period last year[4] - Net profit attributable to shareholders for the same period was ¥165,041,086.70, up 30.50% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥165,101,415.02, reflecting a significant increase of 51.76% compared to the previous year[4] - The company reported a 36.93% increase in net profit attributable to shareholders for the year-to-date period, totaling ¥390,176,301.10[4] - Net profit for the period was CNY 390,176,301.10, representing a 37% increase compared to CNY 284,946,031.60 in the previous year[39] - The total comprehensive income for the period reached ¥390,176,301.10, compared to ¥284,946,031.60 in the previous period, representing an increase of approximately 37%[43] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,455,245,679.97, marking a 45.79% increase from the end of the previous year[4] - Total assets reached CNY 4,455,245,679.97, an increase of 45.7% compared to CNY 3,055,999,316.62 last year[34] - The company's total liabilities increased by 85.92% to ¥315,651,181.00 due to short-term borrowing for working capital[9] - Total liabilities amounted to CNY 1,846,700,406.76, a significant increase from CNY 1,016,848,007.93 year-on-year[35] - Short-term borrowings increased to CNY 315,651,181.00, compared to CNY 169,773,525.00 in the same period last year[34] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥156,679,118.33, showing a 43.47% increase compared to the same period last year[4] - Cash inflow from operating activities totaled ¥1,417,676,860.54, up from ¥1,154,502,270.42, indicating a rise of about 22.8%[44] - Net cash flow from operating activities was ¥156,679,118.33, compared to ¥109,210,599.47, showing an increase of about 43.3%[47] - Cash inflow from financing activities amounted to ¥1,372,325,849.73, up from ¥920,352,893.97, representing an increase of approximately 49.2%[50] - The net cash flow from financing activities was ¥905,996,049.53, compared to ¥623,221,736.79, indicating a growth of about 45.3%[50] - The ending balance of cash and cash equivalents was ¥623,880,152.83, compared to ¥428,367,728.56 in the previous period, reflecting an increase of approximately 45.5%[50] Shareholder Information - The company's basic earnings per share for Q3 2021 was ¥0.37, an increase of 27.85% year-on-year[4] - Basic and diluted earnings per share both increased to ¥0.89 from ¥0.65, reflecting a growth of 36.9%[43] - As of September 30, 2021, the company had 1.13 million shares of restricted stock remaining after the first unlock period, which represents 0.1271% of the total share capital[25] Inventory and Expenses - Inventory levels rose significantly by 198.71% to ¥281,054,779.46, indicating increased production and R&D material requirements[9] - Research and development expenses increased to CNY 204,105,266.69, a rise of 23.3% from CNY 165,400,436.31 year-on-year[39] - Cash outflow for purchasing goods and services was ¥720,757,934.03, compared to ¥523,780,105.91 in the previous period, marking an increase of approximately 37.6%[47] Other Financial Metrics - The weighted average return on equity decreased by 6.92% to 7.22% in the current reporting period[4] - The company's fixed assets increased to RMB 701.34 million, up from RMB 536.60 million, reflecting a growth of 30.6%[29] - Non-current assets totaled CNY 2,583,421,577.53, up 42% from CNY 1,823,214,597.62 in the previous year[34] - The company issued 8.5 million convertible bonds in February 2021, with a conversion price adjusted to RMB 46.03 per share effective from July 9, 2021[22] - The company plans to implement a second employee stock ownership plan, which has been approved and is currently in progress[23] - The company reported a significant increase in prepayments, which rose to RMB 61.04 million from RMB 37.06 million, marking a growth of 64.8%[29] - The company’s investment properties decreased slightly to RMB 24.64 million from RMB 26.21 million, indicating a decline of 6%[29] Audit Information - The company did not undergo an audit for the third quarter report[51]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 623,056,090.07, representing a 55.11% increase compared to CNY 401,680,875.78 in the same period last year[27]. - The net profit attributable to shareholders for the first half of 2021 was CNY 225,135,214.40, up 42.06% from CNY 158,477,357.61 in the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 219,494,393.01, reflecting a 39.27% increase from CNY 157,608,676.25 year-on-year[27]. - The net cash flow from operating activities was CNY 62,368,223.31, which is a 21.36% increase compared to CNY 51,389,123.19 in the same period last year[27]. - Basic earnings per share for the first half of 2021 were CNY 0.52, an increase of 44.44% from CNY 0.36 in the previous year[27]. - Diluted earnings per share were CNY 0.50, up 38.89% from CNY 0.36 year-on-year[27]. - Total assets at the end of the reporting period were CNY 4,154,893,453.26, a 35.96% increase from CNY 3,055,999,316.62 at the end of the previous year[27]. - Net assets attributable to shareholders at the end of the reporting period were CNY 2,423,787,409.00, an 18.86% increase from CNY 2,039,151,308.69 at the end of the previous year[27]. Research and Development - The company has a strong R&D team with over 430 personnel, accounting for nearly one-third of the total workforce of over 1,100 employees[49]. - The company holds over 59 patents, including 56 invention patents, and has 136 product approval numbers, with 55 for domestic chemical drugs and 55 for overseas formulations[38]. - The company plans to continue focusing on high-end generic drugs and aims to enhance its product pipeline in innovative drugs targeting major diseases[42]. - Research and development expenses increased by 59.28% to ¥121,728,697.56 from ¥76,423,294.44, indicating a strong commitment to innovation[91]. - The company has a robust pipeline of research projects that are expected to drive future growth and long-term development[86]. Market Presence and Sales - The company has established a marketing network covering over 15,000 medical institutions across all provinces, cities, and autonomous regions in China, including over 4,000 secondary and higher-level hospitals[87]. - The company has signed exclusive sales contracts with multiple distributors in Europe and the United States, expanding its international market presence[87]. - The company is focused on expanding its market presence through strategic product offerings and compliance with national essential drug lists[56]. - The company is actively expanding its market presence through global registration strategies and product diversification[76]. - The company focuses on market expansion through collaboration with distributors and direct sales to retail pharmacies[68]. Production and Quality Management - The company has established high-end manufacturing bases in Haikou, Hangzhou, and Anqing, covering various dosage forms including injections, tablets, and capsules[39]. - The company has established a complete GMP management system in compliance with requirements from the FDA, EMA, WHO, and NMPA, ensuring standardized production processes[63]. - Quality inspections are mandatory for all incoming materials, ensuring compliance with national and internal standards before storage[61]. - Each batch of products must pass strict quality inspections before being released for sale, ensuring compliance with quality standards[65]. - The company implements a dual-lock management system for special and hazardous materials, enhancing safety in material storage[62]. Financial Management and Investments - The total amount of raised funds was ¥169,216.66 million, with ¥16,119.26 million invested during the reporting period[101]. - The company has pledged assets including real estate and land use rights valued at ¥29,279,549.92 as collateral for loans[98]. - The total committed investment amount for the annual production line project is CNY 21,435.29 million, with a cumulative investment of CNY 21,500.43 million, achieving an investment progress of 100.30%[106]. - The company plans to temporarily use up to CNY 200 million of idle raised funds to supplement working capital, with a usage period not exceeding 12 months[112]. - The company has confirmed that all related transactions are conducted at market prices, maintaining transparency and fairness in dealings[161]. Risks and Challenges - The company acknowledges potential risks in production and operations, including industry policies and drug development challenges[7]. - The pharmaceutical industry is heavily influenced by national policies, with ongoing pressures from medical insurance cost control and bidding price reductions impacting drug sales[121]. - The company faces risks related to international trade protectionism and globalization challenges, which may affect drug registration and export[121]. - The lengthy and complex R&D process for pharmaceutical products poses significant risks, including market changes post-approval[121]. - Sales of prescription drugs depend heavily on physician awareness and market demand, with potential risks from market competition and promotional activities[121]. Corporate Governance and Social Responsibility - The company has committed to transparency in its operations, ensuring that any potential conflicts of interest are managed appropriately[142]. - The company actively engages in social responsibility, including a donation of over 5 million yuan worth of medicines to aid flood relief efforts in Zhengzhou[135]. - The company has not faced any environmental penalties and adheres to strict environmental protection regulations during its operations[134]. - The company has made commitments to avoid unfair benefit transfers and to ensure that executive compensation is linked to the execution of return compensation measures[142]. - The company has reported no overdue commitments as of the end of the reporting period, indicating strong compliance with its obligations[139].

Financial Performance - The company's operating revenue for 2020 was ¥1,188,603,424.51, representing a 25.10% increase from ¥950,095,207.86 in 2019 [22]. - The net profit attributable to shareholders for 2020 was ¥407,450,895.97, a 35.30% increase from ¥301,147,028.57 in 2019 [22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥380,235,764.93, up 34.14% from ¥283,461,483.69 in 2019 [22]. - The net cash flow from operating activities for 2020 was ¥332,075,817.29, a significant increase of 54.19% compared to ¥215,374,300.86 in 2019 [22]. - The total assets at the end of 2020 reached ¥3,055,999,316.62, marking a 77.64% increase from ¥1,720,306,871.36 at the end of 2019 [22]. - The net assets attributable to shareholders at the end of 2020 were ¥2,039,151,308.69, up 77.95% from ¥1,145,941,429.17 at the end of 2019 [22]. - The company reported a basic and diluted earnings per share of ¥0.94 for 2020, a 32.39% increase from ¥0.71 in 2019 [22]. - In 2020, the company achieved operating revenue of CNY 1,188.60 million, a year-on-year increase of 25.10% [77]. - The net profit attributable to shareholders reached CNY 407.45 million, up 35.30% year-on-year [77]. - Total assets increased to CNY 3,055.99 million, a growth of 77.64% compared to the previous year [77]. Dividend Distribution - The company plans to distribute a cash dividend of 1.87 RMB per 10 shares to all shareholders, based on a total of 437,029,279 shares [6]. - The total cash dividend distributed was RMB 81,724,475.17, representing 20.06% of the net profit attributable to shareholders [166]. - The company reported a distributable profit of RMB 842,731,626.18 for the year 2020 [163]. - Over the past three years, the cash dividend distribution has been consistent, with 2018 at RMB 38,467,050.30, 2019 at RMB 60,448,142.91, and 2020 at RMB 81,724,475.17 [166]. - The company has maintained a cash dividend payout ratio of approximately 20% over the last three years [166]. - The company has not proposed any capital reserve conversion or stock bonuses for the reporting period [163]. - The company has complied with its profit distribution plan as per its articles of association [162]. - The company’s profit distribution plan aligns with the legal requirements and internal regulations [162]. Research and Development - The company has a total of over 70 ongoing research projects, including generic drugs and improved new drugs [35]. - The company has a strong emphasis on R&D, with a dedicated expert committee guiding major technology projects and evaluations [69]. - R&D personnel increased by 24.81% year-on-year, significantly higher than the overall employee growth rate [82]. - Total R&D investment reached ¥283,151,872.64, representing 23.82% of operating revenue, an increase from 21.51% in 2019 [114]. - The company is focusing on developing generic drugs, with 25 projects classified as NP (New Product) and 12 as ANDA (Abbreviated New Drug Application) [89]. - The company is committed to increasing R&D investment, focusing on high-difficulty generic drugs with good future competitive landscapes, ensuring the launch of high-value products [152]. - The company is actively pursuing consistency evaluations for its products, as those that fail to meet standards may adversely affect future operations [156]. Market Expansion and Sales - The company has established a marketing network covering over 15,000 medical institutions across all provinces, cities, and autonomous regions in China, including more than 3,700 secondary and higher-level hospitals [69]. - The company has signed exclusive sales contracts with multiple distributors in Europe and the United States, expanding its international market presence [69]. - The company is actively pursuing market expansion with multiple projects in the pipeline, including 8 projects in the United States and 6 in the European Union [89]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain [175]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential M&A activities [175]. - The company plans to deepen its product chain in areas such as anti-allergy, anti-tumor, and cardiovascular medications while exploring international innovative drugs [86]. Production and Quality Control - The company has established a comprehensive GMP management system in compliance with standards set by the FDA, EMA, WHO, and NMPA, ensuring standardized production processes [50]. - The company has implemented strict quality control measures throughout the production process, ensuring compliance with high-quality standards [61]. - Quality inspections are mandatory for all incoming materials, ensuring compliance with national and internal standards before storage [46]. - The company has established a procurement model based on "production-driven purchasing," ensuring raw materials are acquired according to production plans and inventory levels [43]. - A strict supplier management system is in place, requiring suppliers to meet specific production qualifications and undergo regular evaluations [44]. Strategic Focus and Future Plans - The company’s strategic focus is on differentiation, integration of raw materials and formulations, and internationalization in high-end manufacturing [76]. - The long-term strategy includes dual submissions for innovative drugs in both the U.S. and China, targeting multiple therapeutic areas [152]. - The company is focusing on transitioning from international generic drugs to international innovative drugs, with a short-term strategy emphasizing high-end generic drug manufacturing and compliance in global production capabilities [150]. - The company is committed to expanding its international market presence despite the complexities of the current global situation [86]. Compliance and Governance - The company has maintained a continuous relationship with Tianjian Accounting Firm for 8 years, with an audit fee of 900,000 RMB [191]. - The company’s management has committed to ensuring that any misleading statements in the prospectus will lead to compensation for investors [184]. - The company has not faced any bankruptcy reorganization matters during the reporting period [192]. - The company reported no non-operating fund occupation by controlling shareholders during the reporting period [187]. Legal and Contractual Matters - The arbitration case with Zhongtian Construction involves a dispute over the construction cost of the injection production building, with an amount in dispute of 23.06 million yuan [193]. - The contract dispute with Nanjing Kavin Dishi has an amount in dispute of 3.66 million yuan, with no significant adverse impact on the company's main products or core patents [193].